ClinicalTrials.Veeva

Menu

Comparison of Nodal Staging in Endometrial Cancer

F

Frederick R. Ueland, M.D.

Status and phase

Terminated
Phase 3

Conditions

Endometrial Cancer

Treatments

Procedure: Sentinel node procedure
Procedure: Selective staging

Study type

Interventional

Funder types

Other

Identifiers

NCT04970368
MCC-21-GYN-210

Details and patient eligibility

About

This study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging.

Enrollment

38 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy
  • Histologically or cytologically confirmed endometrioid-type endometrial cancer confined to the uterine corpus
  • No clinical evidence of extra-uterine disease on pre-operative evaluation.
  • Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy.
  • Age ≥18 years.
  • Life expectancy (estimated survival) of at least 6 months.
  • AST(SGOT)/ALT(SGPT) < 3.0X upper limit of normal
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

  • GOG/ECOG Performance Status greater than 2
  • Non-endometrioid cell type
  • Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam
  • Previous vaginal, pelvic or abdominal irradiation
  • Chemotherapy, hormone therapy or immunotherapy directed at the present disease
  • Previous pelvic lymphadenectomy or retroperitoneal surgery
  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
  • Known allergy to iodine or indigocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or lactating women

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

38 participants in 2 patient groups

Sentinel Node Surgical Staging
Experimental group
Treatment:
Procedure: Sentinel node procedure
Selective Surgical Staging
Experimental group
Treatment:
Procedure: Selective staging

Trial contacts and locations

1

Loading...

Central trial contact

Frederick Ueland, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems